Gland B2B Business Model and Growth Strategy slide image

Gland B2B Business Model and Growth Strategy

Promoted by Shanghai Fosun Pharma Shanghai Fosun Pharma is Global Pharmaceutical Major with Extensive Pharmaceutical Manufacturing, Distribution and R&D Expertise Globally FOSUN PHARMA 复星医药 Fosun Pharma is a Global pharmaceutical major, whose shares are listed on the Shanghai Stock Exchange and the Stock Exchange of Hong Kong Limited (1) Relationship with Shanghai Fosun Pharma provides widened market access opportunities arising from its own continuing internationalization Benefitted from Shanghai Fosun Pharma's established presence in China and Africa, both of which we consider to be key growth markets for injectables Continue Strategic Alignment with Shanghai Fosun Pharma to Increase Market Reach Leverage existing infrastructure and global presence to access new markets, including China and Africa Benefit from regulatory know-how to navigate the rapidly evolving healthcare landscape in China 32 32 (1) Market cap of US$ 15.0 bn as of March 31, 2021. Benefit from bargaining power and scale to procure raw materials & equipment from China Access extensive sales, logistics and distribution network to enable market penetration in China Leverage ability to access key markets to provide coverage for a portfolio of products GLAND
View entire presentation